5 recruiting, 2 active not recruiting, 2 completed, 1 terminated. 4 Not applicable, 2 Phase 3, 1 Early Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 4 | Active not recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
| Early Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Hormone Receptor-Positive Breast Carcinoma: new trials by email Literature Review of Hormone Receptor-Positive Breast Carcinoma trials Research Report on Hormone Receptor-Positive Breast Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Sleep After Breast Cancer (ABC) Study - Examining Sleep Changes and Biomarkers Among Breast Cancer Patients Non-Interventional Study - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Recruiting | Ohio State University Comprehensive Cancer Center | 100 | 2025-08-18 | 2026-01-14 | |
| 5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss Biospecimen Collection, Bone Mineral Density Test, Questionnaire Administration - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Phase 2 | Recruiting | Mayo Clinic | 38 | 2025-07-25 | 2026-08-10 |
| Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer Acupressure Therapy, Acupuncture Therapy, Aromatase Inhibition Therapy - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Not applicable | Recruiting | Emory University | 150 | 2024-12-12 | 2026-01-29 |
| Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer Biospecimen Collection, Cyclophosphamide, Doxorubicin - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 | Phase 3 | Recruiting | National Cancer Institute (NCI) | 3680 | 2023-11-27 | 2026-10-22 |
| Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) Non-Interventional Study - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Completed | Mayo Clinic | 105 | 2023-07-12 | 2025-10-31 | |
| Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study Best Practice, Biospecimen Collection, Endocrine Drug Therapy - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Not applicable | Active not recruiting | SWOG Cancer Research Network | 565 | 2023-03-29 | 2026-04-02 |
| A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy Best Practice, Internet-Based Intervention, Questionnaire Administration - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Not applicable | Terminated | Emory University | 21 | 2023-03-21 | 2026-04-17 |
| Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer Letrozole, Simvastatin - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Early Phase 1 | Recruiting | Emory University | 40 | 2022-09-02 | 2026-07-17 |
| Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer Best Practice, Biopsy, Biospecimen Collection - Advanced Breast Adenocarcinoma, Advanced HER2-Negative Breast Carcinoma | Not applicable | Withdrawn | City of Hope Medical Center | 2022-07-03 | 2022-06-09 | |
| National Cancer Institute "Cancer Moonshot Biobank" Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8 | Active not recruiting | National Cancer Institute (NCI) | 1600 | 2020-11-11 | 2026-10-05 | |
| Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Aromatase Inhibition Therapy, Carboplatin, Cytology Specimen Collection Procedure - HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 315 | 2014-02-18 | 2026-10-06 |
Breast Carcinoma In Situ (2) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Lung Neoplasms (1) · Melanoma (1) · Multiple Myeloma (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1) · Small Cell Lung Carcinoma (1) · Stomach Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Breast Diseases (5) · Neoplasms (5) · Neoplasms by Site (5) · Skin Diseases (5) · Skin and Connective Tissue Diseases (5) · Breast Neoplasms (3) · Neoplasms by Histologic Type (3) · Carcinoma (2) · Carcinoma in Situ (2) · Neoplasms, Glandular and Epithelial (2) · Adnexal Diseases (1) · Blood Protein Disorders (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Cardiovascular Diseases (1)
Specimen Handling (4) · Practice Guidelines as Topic (3) · Aromatase Inhibitors (2) · Standard of Care (2) · 2C4 antibody (1) · Acupressure (1) · Acupuncture Therapy (1) · Biopsy (1) · Bone Density (1) · CT-P6 (1) · Carboplatin (1) · Cyclophosphamide (1) · Disulfides (1) · Docetaxel (1) · Doxorubicin (1)
Emory University (3) · National Cancer Institute (NCI) (3) · Mayo Clinic (2) · City of Hope Medical Center (1) · Ohio State University Comprehensive Cancer Center (1) · SWOG Cancer Research Network (1)
United States (10) · Puerto Rico (3) · Peru (1)
Barbara K. Bruce, Ph.D., L.P. (1) · Demetria Smith-Graziani, MD,MPH (1) · Electra Paskett, MSPH, PhD, FAACR (1) · Erin F Cobain (1) · Jane L. Meisel, MD (1) · Lyndsay N Harris (1) · Mothaffar F Rimawi (1) · Norah L Henry (1) · Ruth L. Sacks, MD (1) · Saranya Chumsri, MD (1) · Yuan Yuan (1)
P30CA138292 (3), P30CA033572 (1), R01CA266012 (1), U10CA012027 (1), U10CA180868 (1), U10CA180888 (1), UG1CA189974 (1)